Wutah pendapatan taun lumaku: Monopar Corp (MNPR)

Logo perusahaan publik monopartx.com (MNPR)

Monopar Therapeutics (MNPR) focuses on the B2B segment, developing tools to minimize chemotherapy side effects in clinics. The year-over-year (12-month) relative revenue growth rate reflects the development trend, with the indicator standing at 0.00. US centers that reduce treatment toxicity ensure the business's stability. The company is currently moving its promising radiopharmaceutical pipeline and targeted drugs into the early clinical testing stage.

Monopar Therapeutics (MNPR): Wutah pendapatan YoY sajrone 12 wulan kepungkur saka 11.02.2024 nganti 18.11.2026

Monopar Therapeutics - rincian analitis lan metrik utama (MNPR)

- rega saham lan target rega konsensus:
- indikator kapitalisasi bursa perusahaan:
Ringkesan analitik perusahaan:Monopar Pharma
Produk merek Monopar Corp

This indicator measures the revenue growth rate over a rolling year, smoothing out short-term anomalies to assess the actual operational resilience of the business. For Monopar Therapeutics (MNPR), which focuses on radiopharmaceutical R&D, the TTM revenue growth rate serves as a marker for the transition from pure funding to the commercialization of innovations, where a lack of growth coupled with high research expenditures signals high risks for capital.

Karo sapa Monopar Therapeutics saingan

Incyte Pharma - Wutah dodolan YoY sajrone rolas wulan kepungkur|HUTCHMED Corp - Wutah dodolan YoY (TTM)|Wutah pendapatan taun lumaku Nuvation Bio Inc.|DAWN: Wutah dodolan YoY (TTM)|Tingkat wutah pendapatan YoY sajrone rolas wulan kepungkur Inhibrx Biosciences Inc INBX|Wutah pendapatan YoY sajrone 12 wulan kepungkur IMAB|Wutah pendapatan taun lumaku Fennec Pharmaceuticals FENC|Wutah pendapatan YoY sajrone 12 wulan kepungkur HRTX (Heron)|NVCT (Nuvectis Pharma) - Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Coherus Biosciences - Wutah pendapatan YoY sajrone 12 wulan kepungkur|Owah-owahan pendapatan YoY sajrone 12 wulan kepungkur CRBP (Corbus Pharmaceuticals Holdings)|Cardiff Oncology - Wutah dodolan YoY (TTM)|Dinamika pendapatan YoY sajrone rolas wulan kepungkur BYSI (BeyondSpring Pharma)|BCAB: Wutah dodolan YoY (TTM)|Wutah pendapatan taun lumaku lixte.com (LIXT)|Wutah dodolan YoY sajrone rolas wulan kepungkur citiuspharma.com|CLRB: Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Wutah dodolan YoY (TTM) BLRX|Wutah dodolan YoY (TTM) Can-Fite (CANF)|Wutah dodolan YoY sajrone rolas wulan kepungkur Aprea Therapeutics Inc. APRE|KZIA (kaziatherapeutics.com) - Wutah dodolan taun lumaku|SLXN: Wutah pendapatan YoY sajrone 12 wulan kepungkur|Wutah pendapatan taun lumaku NuCana|CMRX: Wutah dodolan YoY (TTM)|Wutah pendapatan YoY sajrone 12 wulan kepungkur Cyclacel Pharmaceuticals|GTHX (g1therapeutics.com) - Wutah dodolan YoY (TTM)|KRON: Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Wutah dodolan YoY sajrone rolas wulan kepungkur Kintara (KTRA)|Wutah pendapatan YoY sajrone 12 wulan kepungkur Oncternal ONCT|Portage Biotech - Wutah pendapatan YoY sajrone 12 wulan kepungkur